Terns Pharmaceuticals Inc., a biopharmaceutical company listed on the Nasdaq, has been making significant strides in the healthcare sector, particularly in the development of molecularly-targeted and oral molecule drugs aimed at treating liver disease and cancer. Based in Foster City, United States, the company has established a global presence, serving customers worldwide. As of November 6, 2025, Terns Pharmaceuticals’ stock closed at $18.47, reflecting a slight decrease from its 52-week high of $18.75, recorded on November 3, 2025. However, this price is substantially higher than its 52-week low of $1.865, observed on April 6, 2025.
With a market capitalization of $1.6 billion USD, Terns Pharmaceuticals has demonstrated resilience and growth potential in a competitive industry. Despite facing challenges, as indicated by a negative price-to-earnings ratio of -17.46, the company continues to focus on its core mission of developing innovative treatments for critical health conditions.
Terns Pharmaceuticals’ commitment to advancing medical science is evident in its strategic focus on liver disease and cancer, areas where there is a significant unmet medical need. By leveraging cutting-edge research and development, the company aims to bring new, effective therapies to market, potentially transforming patient outcomes and improving quality of life.
For those interested in learning more about Terns Pharmaceuticals’ activities and offerings, further information is available on their official website at www.ternspharma.com . The company’s dedication to innovation and patient care positions it as a key player in the biopharmaceutical industry, with the potential to make substantial contributions to global health.
